FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or it’s antigen-binding fragment, binding specificity for CD40. Also disclosed is an immunoconjugate, comprising said antibody or antigen-binding fragment, a nucleic acid molecule, encoding said antibody or a fragment thereof, an expression vector containing the said nucleic acid, a host cell containing said vector, a pharmaceutical composition, comprising said antibody or a fragment thereof. Use of an antibody or antigen-binding fragment, a method of treating an individual, with the use of said antibody or fragment thereof, is disclosed.
EFFECT: invention has the ability of binding specificity for CD40, thereby effectively treating cancer associated with CD40 expression.
61 cl, 14 ex, 12 tbl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| HIGH-AFFINITY ANTI-CD3 ANTIBODIES AND METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2831840C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
| HUMANISED ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2407544C2 |
| ANTI-ILT2 ANTIBODIES AND USE THEREOF | 2020 |
|
RU2832673C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
